YP2A Stock Overview
A commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BioLineRx Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.22 |
| 52 Week High | ₪1.60 |
| 52 Week Low | ₪0.22 |
| Beta | 0.87 |
| 11 Month Change | -27.03% |
| 3 Month Change | -63.70% |
| 1 Year Change | -84.23% |
| 33 Year Change | -90.27% |
| 5 Year Change | -90.69% |
| Change since IPO | -99.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| YP2A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -46.8% | -0.2% | 0.8% |
| 1Y | -84.2% | -16.9% | 9.1% |
Return vs Industry: YP2A underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: YP2A underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| YP2A volatility | |
|---|---|
| YP2A Average Weekly Movement | 20.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YP2A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: YP2A's weekly volatility has increased from 16% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 79 | Phil Serlin | www.biolinerx.com |
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.
BioLineRx Ltd. Fundamentals Summary
| YP2A fundamental statistics | |
|---|---|
| Market cap | €23.52m |
| Earnings (TTM) | -€28.70m |
| Revenue (TTM) | €16.24m |
1.4x
P/S Ratio-0.8x
P/E RatioIs YP2A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YP2A income statement (TTM) | |
|---|---|
| Revenue | US$17.05m |
| Cost of Revenue | US$6.04m |
| Gross Profit | US$11.00m |
| Other Expenses | US$41.12m |
| Earnings | -US$30.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 64.55% |
| Net Profit Margin | -176.67% |
| Debt/Equity Ratio | 210.6% |
How did YP2A perform over the long term?
See historical performance and comparison